Skip to main content
Premium Trial:

Request an Annual Quote

Axela Acquires Xceed Molecular

NEW YORK (GenomeWeb News) – Axela today announced that it has acquired Xceed Molecular for an undisclosed sum.

The deal combined Axela's multiplex protein biomarker testing capabilities with Xceed's Ziplex System for gene expression analysis. Axela said that the new firm, which will operate under its name, will offer clinical researchers a portfolio of products for analysis of proteins, pathogens, DNA, and RNA to speed the validation and clinical application of biomarkers.

Axela CEO Rocky Ganske will serve in the same role for the newly combined firm, which will now be located at Xceed's headquarters in Toronto.

Ganske said the acquisition of Xceed "provides a tremendous opportunity to accelerate introduction of novel multiplex biomarkers for diagnostics. Our focus is to simplify multiplex assay development and validation with robust, easy-to-use tools for analysis of DNA, RNA, and protein biomarkers that are designed to move seamlessly from the clinical-research arena into the workflow of the clinical-diagnostics lab."

Xceed President and CEO David Deems will become president of Axela and oversee sales, marketing, and business development. Deems said in a statement that the complementary technologies are "well-positioned to improve diagnostics in infection, cancer, and other immune-related diseases."

The firms are introducing the new Axela at the 2010 American Association of Clinical Chemistry annual meeting, which is taking place this week in Anaheim, Calif.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.